{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"groups":[{"description":"This is a phase II, single center clinical trial designed to evaluate the response rate and toxicity of a response-adapted, sequential therapy, using bortezomib and dexamethasone, followed by the addition of lenalidomide in non-responders, in patients with untreated MM.\n\nBortezomib: Bortezomib SC (or IV if SC not tolerated) 1.5 mg/m\\^2, days 1, 8, 15 and 22\n\nDexamethasone: Dexamethasone 40 mg PO or IV days 1, 4, 8,15 and 22 or on a split-dose regimen. (20mg BIW).\n\nLenalidomide: Lenalidomide may be added to the patient's regimen at any time if there is evidence of hematologic disease progression","id":"OG000","title":"Patients With Multiple Myeloma"}],"populationDescription":"Data were not collected due to this being a minor objective that is not crucial to the study. Resources were prioritized to primary and secondary outcomes.","reportingStatus":"POSTED","timeFrame":"2 years","title":"Characterization of Genomic Mutations of Targetable Genes","type":"OTHER_PRE_SPECIFIED"}